Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF(159506.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF
159506.SZ
News
View More

"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digested

China Merchants Securities has initiated coverage on Kanion Pharmaceutical, expecting net profits of RMB 1.65 billion, RMB 1.96 billion, and RMB 2.27 billion for the years 2025 to 2027, with annual growth rates of 1.5%, 18.9%, and 15.8%, respectively. The report indicates that Kanion Pharmaceutical has absorbed the impact of centralized procurement and has transformed into a full-chain innovative pharmaceutical company. Although there will be short-term performance fluctuations, the launch of innovative products starting in 2024 is expected to bring a turning point in performance. The company focuses on specialties and operates independently in skin health, ophthalmology, and Southeast Asian markets

AASTOCKS·
SH
512290
+0.87%
SH
516500
+1.21%
SH
513700
-1.61%
AASTOCKS·
SH
512290
+0.87%
SH
516500
+1.21%
SH
513700
-1.61%

Goldman Sachs Raises Price Target for Novo Nordisk to 436 Danish Kroner (352), Reiterates Buy - BN

Goldman Sachs raises its price target for Novo Nordisk to 436 Danish kroner (previously 352), and reiterates its buy recommendation - BN

marketscreener·
SZ
159506
-2.41%
SZ
159849
+1.30%
marketscreener·
SZ
159506
-2.41%
SZ
159849
+1.30%

Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies.

Unusual Whales·
SH
513700
-1.61%
SH
562600
+0.65%
SZ
159506
-2.41%
Unusual Whales·
SH
513700
-1.61%
SH
562600
+0.65%
SZ
159506
-2.41%

Sisram Medical Explores Local Manufacturing Partnership in China with Fosun Unit

Sisram Medical Ltd. has signed a non-binding memorandum of understanding with Sinmait Medical Technology to explore local manufacturing of its energy-based medical devices in China. This partnership aims to shorten supply chains and enhance local responsiveness, positioning China as a regional production hub. The arrangements may be subject to Hong Kong listing rules and further regulatory announcements. The current analyst rating for Sisram Medical stock (HK:1696) is a Hold with a price target of HK$4.50.

Tip Ranks·
SH
600196
+2.14%
SZ
159506
-2.41%
SH
520690
-1.39%
Tip Ranks·
SH
600196
+2.14%
SZ
159506
-2.41%
SH
520690
-1.39%

Everest Medicines Signs Lease Agreement for New Premises

Everest Medicines Limited has signed a lease agreement through its subsidiary, Everest Medicines Trading (Shanghai) Co., Ltd., with Kang Pu as the lessor. The agreement involves leasing certain premises for a specified term. Mr. Wei Fu, a non-executive director with a material interest in the transaction, abstained from voting on the board resolutions. The company confirmed compliance with the Hong Kong Listing Rules regarding necessary approvals.

Reuters·
SZ
159506
-2.41%
SH
520690
-1.39%
SH
516500
+1.21%
Reuters·
SZ
159506
-2.41%
SH
520690
-1.39%
SH
516500
+1.21%
© 2026 Longbridge｜Disclaimer